October 18, 2021

Medical Trend

Medical News and Medical Resources

Israeli data: Protection of booster shot of Pfizer vaccine restored to 95%

Israeli data: Protection of booster shot of Pfizer vaccine restored to 95%.

Israeli data: Protection rate of booster shot of Pfizer COVID-19 vaccine restored to 95%



Israeli data: Protection of booster shot of Pfizer vaccine restored to 95%.  Israeli data show that the protection rate of booster shot of Pfizer COVID-19 vaccine can be restored to 95%

According to a 52-page report submitted by Pfizer to the U.S. Food and Drug Administration (FDA), Israeli clinical data show that 6 months after the second dose of vaccine, the third dose of Pfizer vaccine can protect against infection. The rate returned to 95%.

The report data was collected from July 1st to August 30th, a period of time when the Delta virus variants are raging around the world. Israel is one of the first countries in the world to receive Pfizer vaccine. The protection rate of its mRNA vaccine has been significantly weakened over time, but the results show that the third injection can return the protection rate to the highest value.

Pfizer also announced the results of an immune response study conducted on more than 300 people. The results showed that the third dose of vaccination significantly increased the level of antibodies in the blood. The antibody level one month after the third dose was more than three times that of one month after the second dose.

Therefore, Pfizer concluded that based on the similarities between the outbreaks in Israel and the United States, it is necessary to consider the third-quarter booster within 6 months after the second dose. The company said it is applying for permission to vaccinate people over the age of 16.

 

 


FDA is under pressure

At present, the FDA is not only facing pressure from Pfizer in reviewing enhanced needles. White House Chief Medical Advisor Fauci has said that the FDA may approve Pfizer’s COVID-19 vaccine booster before September 20.

FDA staff refused to express a position on the enhanced needle within days, saying that the agency has not yet verified all available data. The official website document reads, “The FDA has not independently reviewed and verified the data or its conclusions.” Regarding the Israeli data, the FDA stated that “because observational studies do not meet the same standards as formal clinical trials, FDA staff are skeptical about the data. .”

Earlier this month, Marion Gruber and Phil Krause, the chief and deputy directors of the Office of Vaccine Research and Review under the FDA’s Center for Biologics Evaluation and Research (CBER), resigned. They have worked in the agency for 32 years and 10 years, respectively.

Media reports stated that the reason for resignation was because they were dissatisfied with the White House’s practice of strengthening needles. The two officials believed that the Centers for Disease Control and Prevention (CDC) had made the decision that the FDA should have made. The FDA has not yet decided whether to implement the enhanced injection and the US government announced the plan.

Many American scientists and health experts have repeatedly criticized the plan to strengthen the needle, saying that the data cited by federal health officials are not convincing and that the government is too early to promote the plan. Harvard Medical School immunologist Dan Barouch said that there is currently no consensus in the biomedical community to promote the third injection to the general public.

(source:internet, reference only)


Disclaimer of medicaltrend.org